Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis
复制标题
1α-羟基维生素D3对绝经后骨质疏松症患者腰椎骨密度及椎体骨折的影响
DOI：
--
复制
发表时间：
1994
影响因子：
4.2
通讯作者：
N. Ogawa
中科院分区：
文献类型：
--
作者：
H. Orimo;M. Shiraki;Yoshihiko Hayashi;Tadayoshi Hoshino;T. Onaya;S. Miyazaki;H. Kurosawa;Tetsumi Nakamura;N. Ogawa
1α-羟基维生素D3[1α(OH)D3]对骨密度、骨折发生率和骨代谢的影响通过双盲、安慰剂对照研究进行评估。80例绝经后骨质疏松症日本妇女，平均年龄(71.9±7.3)岁，随机分为1μg组和1α(OH)D3组，每日1次，对照组服用非活性安慰剂1年。所有患者都补充钙(每天300毫克的元素钙)。双能X线骨密度仪测定腰椎(L2-L4)骨密度：1α(OH)D3组增加0.65%，安慰剂组下降1.14%(P=0.037)。股骨颈和Ward‘s三角的骨密度两组间无显著差异，而1α(OH)D3治疗组大鼠股骨粗隆骨密度增加4.20%，安慰剂组下降2.37%(P=0.055)。X射线分析显示，2名服用1α(OH)D3的患者和7名服用安慰剂的患者出现了新的椎体骨折。治疗组椎体骨折发生率(75/1000病人年)明显低于对照组(277/1000病人年；P=0.029)。1例接受1α(OH)D3治疗的患者出现高钙血症(12.1 mg/100ml)，但在停止治疗后，该患者的血钙水平迅速下降至参考范围。两组患者的血清肌酐水平均无明显变化。治疗组尿钙排泄量明显增加，但羟脯氨酸排泄量无明显变化。治疗后血清骨源性碱性磷酸酶活力较治疗前明显下降，−为26±26(mU/ml)(P=0.003)。这些结果表明，1α(OH)D3治疗绝经后骨质疏松症有效地维持了骨小梁的质量，防止了进一步的椎体骨折，且没有任何严重的不良反应。
The effects of 1α-hydroxyvitamin D3 [1α(OH)D3] on bone mineral density, fracture incidence, and bone metabolism were evaluated by a double-blind, placebo-controlled study. Eighty postmenopausal osteoporotic Japanese women (71.9±7.3 years, mean±SD) were randomly assigned to 1 μg of 1α(OH)D3 daily or inactive placebo for 1 year. All patients were given supplemental calcium (300 mg of elemental calcium daily). Lumbar (L2–L4) bone mineral density (BMD) determined by dual energy X-ray absorptiometry increased 0.65% with 1α(OH)D3 treatment and decreased 1.14% with placebo (P=0.037). BMD in both the femoral neck and Ward's triangle did not yield any significant differences between the two groups, whereas trochanter BMD in the 1α(OH)D3-treated group increased 4.20% and decreased 2.37% with placebo (P=0.055). X-ray analysis demonstrated that new vertebral fractures occurred in two patients with 1α(OH)D3 and in seven patients with placebo. The vertebral fracture rate in the treated group was significantly less (75/1000 patient years) than in the control group (277/1000 patient years; P=0.029). Hypercalcemia (12.1 mg/100 ml) occurred in one patient receiving 1α(OH)D3; however, the serum calcium level in this patient promptly decreased to the reference range after cessation of the treatment. There were no significant changes in serum creatinine level in either group. A significant increase in urinary excretion of calcium was found but there was no significant change in urinary excretion of hydroxyproline in the treated group. The serum level of bone-derived alkaline phosphatase activity significantly decreased by−26±26 (mU/ml) after the treatment (P=0.003). These results indicate that 1α(OH)D3 treatment is effective for maintaining trabecular bone mass and prevents further vertebral fractures without any serious adverse effects in postmenopausal osteoporosis.
人血浆中 1,25-二羟基维生素 D 的改进放射性受体测定。
影响因子：
2.9
作者：
Dokoh,S;Pike,JW;Chandler,JS;Mancini,JM;Haussler,MR
通讯作者：
Haussler,MR
影响因子：
39.2
作者：
S. Ott;C. Chesnut
通讯作者：
S. Ott;C. Chesnut